Katibeh Marzieh, Kalantarion Masumeh, Mariotti Silvio Paolo, Safi Sare, Shahraz Saeid, Kallestrup Per, Rahmani Saeed, Mohammadi Seyed-Farzad, Mahdavi Alireza, Ahmadieh Hamid
Center for Global Health, Aarhus University, Aarhus, Denmark, Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arch Iran Med. 2017 May;20(5):288-294.
To assess the national health system for management of diabetes mellitus (DM) in Iran, with particular focus on diabetic retinopathy (DR).
In this qualitative study, the national stakeholders related to DR and DM management system were invited to participate. Two researchers performed interview using a semi-structured questionnaire recommended by the World Health Organization titled "Tool for Assessment of Diabetic Retinopathy and DM Management Systems". The questionnaire contains seven different sections, each consisting of closed and open-ended questions, and a final Likert-type score, ranging from 1 indicating the worst to 4 indicating the best status. Inconsistencies were resolved through a collective decision of the research team, followed by a focus group discussion with stakeholders at the Ministry of Health.
Fourteen stakeholders out of 15 total invitees were interviewed (response rate: 93.3%). There were national priorities, defined policies, and running programs (score = 3), but the care system should be strengthened in terms of implementation of clinical guidelines, with specific reference to the availability of regular screenings for DR (score = 2). The network of care providers, health information systems, and promotional programs were insufficient (score = 2). The health workforce and technology for DR and DM were acceptable (scores 4 and 3, respectively); however, there were concerns about the appropriate distribution and utilization of resources and out-of-pocket costs paid by patients.
The existence of national policies, programs, a qualified workforce, and modern technology is promising. Nevertheless, other aspects of the health system need to be improved to ensure access to health and eye care for people with DM and achieve universal health coverage.
评估伊朗国家卫生系统对糖尿病(DM)的管理情况,尤其关注糖尿病视网膜病变(DR)。
在这项定性研究中,邀请了与DR和DM管理系统相关的国家利益相关者参与。两名研究人员使用世界卫生组织推荐的名为“糖尿病视网膜病变和DM管理系统评估工具”的半结构化问卷进行访谈。该问卷包含七个不同部分,每个部分由封闭式和开放式问题组成,最后还有一个李克特量表评分,范围从1表示最差到4表示最佳状态。不一致之处通过研究团队的集体决策解决,随后与卫生部的利益相关者进行焦点小组讨论。
总共15名受邀者中有14名利益相关者接受了访谈(回复率:93.3%)。存在国家优先事项、明确的政策和正在实施的项目(评分 = 3),但在临床指南的实施方面,护理系统应得到加强,特别是在定期进行DR筛查的可及性方面(评分 = 2)。护理提供者网络、健康信息系统和推广项目不足(评分 = 2)。用于DR和DM的卫生人力和技术是可以接受的(分别为评分4和3);然而,人们担心资源的合理分配和利用以及患者自付费用。
国家政策、项目、合格的劳动力和现代技术的存在是有希望的。尽管如此,卫生系统的其他方面需要改进,以确保糖尿病患者能够获得健康和眼科护理,并实现全民健康覆盖。